Apatinib has been proven to be effective and safe among patients in the third-line treatment of advanced gastric cancer in phase II and III trials. We aimed to evaluate its efficacy and safety in second-line practice, and to explore the factors associated with efficacy. Between April 2015 and May 2017, a total of 23 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction were enrolled and followed up retrospectively after failing the first line of systemic therapy. The median progression-free survival was 4.43 months (95% confidence interval: 1.63–7.22) and the median overall survival was 9.11 months (95% confidence interval: 8.22–9.99). Two patients achieved a partial response and 14 patients achieved stable disease. The disease control rate was 69.6% and the objective response rate was 8.7%. The most common adverse events over grade 3 were hypertension (8.7%) and thrombocytopenia (8.7%). No treatment-related death was documented during the drug administration. Apatinib is an effective regimen for the second-line treatment of advanced gastric and gastroesophageal cancer with manageable toxicity. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://ift.tt/1hexVwJ * Yong Zhang and Miaomiao Gou contributed equally to the writing of this article. Correspondence to Zhefeng Liu, PhD, General Hospital of People's Liberation Army, Beijing 100853, China Tel: +86 010 66875307; fax: +86 010 66939128; e-mail: liuzhefeng6691@hotmail.com Received September 6, 2017 Accepted November 15, 2017 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
http://ift.tt/2k1BLkU
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου